


L1 HAS NO ANSWERS
L1 STR



G1 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:32:46 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 17210 TO ITERATE

11.6% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 336341 TO 352059
PROJECTED ANSWERS: 96 TO 592

L2 2 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 10:34:21 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 343733 TO ITERATE

100.0% PROCESSED 343733 ITERATIONS 587 ANSWERS
SEARCH TIME: 00.00.14

L3 587 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
187.32	187.54

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:34:42 ON 10 DEC 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Dec 2009 VOL 151 ISS 24
 FILE LAST UPDATED: 9 Dec 2009 (20091209/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 19 L3

=> b stng

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.50	188.04

FILE 'STNGUIDE' ENTERED AT 10:35:29 ON 10 DEC 2009
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Dec 4, 2009 (20091204/UP).

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.14	188.18

FILE 'CAPLUS' ENTERED AT 10:36:27 ON 10 DEC 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Dec 2009 VOL 151 ISS 24
 FILE LAST UPDATED: 9 Dec 2009 (20091209/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s US20070010511/pn
L5          1 US20070010511/PN
```

```
=> file reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY      SESSION
FULL ESTIMATED COST          2.74      190.92
```

FILE 'REGISTRY' ENTERED AT 10:36:54 ON 10 DEC 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

```
STRUCTURE FILE UPDATES:    9 DEC 2009  HIGHEST RN 1196786-45-4
DICTIONARY FILE UPDATES:   9 DEC 2009  HIGHEST RN 1196786-45-4
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

```
=> d his
```

```
(FILE 'HOME' ENTERED AT 10:32:12 ON 10 DEC 2009)
```

```
FILE 'REGISTRY' ENTERED AT 10:32:20 ON 10 DEC 2009
```

```
L1          STRUCTURE UPLOADED
L2          2 S L1
L3          587 S L1 SSS FULL
```

FILE 'CAPLUS' ENTERED AT 10:34:42 ON 10 DEC 2009
L4 19 S L3

FILE 'STNGUIDE' ENTERED AT 10:35:29 ON 10 DEC 2009

FILE 'CAPLUS' ENTERED AT 10:36:27 ON 10 DEC 2009
L5 1 S US20070010511/PN

FILE 'REGISTRY' ENTERED AT 10:36:54 ON 10 DEC 2009

=> tra rn
L6 TRANSFER L5 1- RN : 1646 TERMS
L7 1646 L6

=> s l7 and l3\
L8 0 L7 AND L3\
=> del l8 y

=> s l7 and l3
L8 490 L7 AND L3

=> s l3 not l8
L9 97 L3 NOT L8

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	6.31	212.81

FILE 'CAPLUS' ENTERED AT 10:37:58 ON 10 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Dec 2009 VOL 151 ISS 24
FILE LAST UPDATED: 9 Dec 2009 (20091209/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 18

L10 2 L8

=> s 19

L11 17 L9

=> d bib 110 tot

LIG ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS ON STM
 AN 20041017703 CAPLUS
 IN 141115449
 TI Preparation of 4-(4-piperidinyl)phenols and related compounds as aspartic
 protease inhibitors
 IN Herold, Peter; Mah, Robert; Stutz, Stefany Stojanovic, Aleksandar;
 Tschinke, Vincenzoy Jutterand, Nathalie; Schumacher, Christoph
 PA Special Experiments A-G, Switz.
 SO Eur. Pat. Appl., 67pp.
 CODES: EPX25W
 IT Patent
 LA German
 FAN, CPT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1507032	A1	20041004	EP 2004-111381	20040330
A1 AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, LT, LV, FI, NO, MK, CY, AL, TR, BG, CS, HR, HU, PL, SK, RM, RW, TT, YU				
FRAT EP 2004-102559	A	20050331		

OS MARPAT 141115449
 OSC.G 2 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 RE.CHT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LIG ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS ON STM
 AN 2005108938 CAPLUS
 IN 141115449
 TI Preparation of piperidines as renin inhibitors useful against
 hypertension
 IN Herold, Peter; Mah, Robert; Stutz, Stefany Stojanovic, Aleksandar;
 Tschinke, Vincenzoy Jutterand, Nathalie
 PA Special Experiments A-G, Switz.
 SO PCT Int. Appl., 252 pp.
 CODES: PEX262
 IT Patent
 LA English
 FAN, CPT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041457	A2	20050707	WO 2004-087389	20040330
W1 AE, AG, AL, AM, AT, AU, BA, BE, BG, BW, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, DM, ES, FI, FR, GB, GR, HU, IL, IN, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LB, LG, LI, LU, LV, MA, MD, ME, MG, MK, MN, MU, MW, MY, NZ, OM, OS, PA, PE, PG, PH, PK, PL, PT, RU, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SY, TD, TH, TJ, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW W2 BM, CH, CN, DE, ES, FR, GB, GR, HU, IL, IN, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LB, LG, LI, LU, LV, MA, MD, ME, MG, MK, MN, MU, MW, MY, NZ, OM, OS, PA, PE, PG, PH, PK, PL, PT, RU, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SY, TD, TH, TJ, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW W3 EA, BY, BG, BE, BR, BS, BT, BW, CA, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IL, IN, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LB, LG, LI, LU, LV, MA, MD, ME, MG, MK, MN, MU, MW, MY, NZ, OM, OS, PA, PE, PG, PH, PK, PL, PT, RU, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SY, TD, TH, TJ, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW W4 TT, TZ				
EP 1670769	A1	20040623	EP 2004-020606	20040930
A1 AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, LT, LV, FI, NO, CY, TR, BG, CS, HR, HU, PL, SK				
EP 1961752	A2	20040927	EP 2004-100929	20040930
EP 1961752	A2	20051119		
A1 AT, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IL, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR				
US 20070210511	A1	20070111	US 2004-574108	20040331
US 20090210505	A1	20090108	US 2009-084473	20090306
FRAT CH 2007-1469	A	20071001		
CH 2004-1483	A	20040227		
EP 2004-020606	A3	20040930		
WO 2004-137289	M	20040930		
US 2006-074008	A3	20060331		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN L505 DISPLAY FORMAT
 OS CDBRECT 141115449; MARPAT 141115449
 OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
 RE.CHT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:32:12 ON 10 DEC 2009)

FILE 'REGISTRY' ENTERED AT 10:32:20 ON 10 DEC 2009

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 587 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:34:42 ON 10 DEC 2009

L4 19 S L3

FILE 'STNGUIDE' ENTERED AT 10:35:29 ON 10 DEC 2009

FILE 'CAPLUS' ENTERED AT 10:36:27 ON 10 DEC 2009

L5 1 S US20070010511/PN

FILE 'REGISTRY' ENTERED AT 10:36:54 ON 10 DEC 2009

FILE 'CAPLUS' ENTERED AT 10:37:04 ON 10 DEC 2009

L6 TRA L5 1- RN : 1646 TERMS

FILE 'REGISTRY' ENTERED AT 10:37:04 ON 10 DEC 2009

L7 1646 SEA L6

L8 490 S L7 AND L3

L9 97 S L3 NOT L8

FILE 'CAPLUS' ENTERED AT 10:37:58 ON 10 DEC 2009

L10 2 S L8

L11 17 S L9


=> d ibib abs hitstr tot

111 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)
 ACCESSION NUMBER: 2006184167 CAPLUS
 1451271649
 DOCUMENT NUMBER:
 TITLE:
 INVENTOR(S):
 Baasab, Gregg Jangel, Brian Fleming, Paul Roberts,
 Gravenick, Michael Barry Green, Christopher Hawk,
 Sheila Tenney Hill, Pamela Hill, Kenneth Gregory
 Mullen, Gregory Shacter, Nancy Shaw, Paul
 PATENT ASSIGNER(S):
 SOURCE: AstraZeneca AB, Sweden; AstraZeneca UK Limited
 PCT INT. APPL. NO. AND DATE: 249 pp.
 COBEN P10002
 DOCUMENT TYPE:
 LANGUAGE:
 FAMILY ACC. NUM. COUNT: 1
 PRIORITY INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NO 2004087043	A3	20040824	NO 2004-08429	20040216
Wt At, Ag, Al, An, Ar, As, Au, Ba, Bb, Bc, Bd, Be, Bf, Bg, Bh, Bi, Bj, Bk, Bl, Bm, Bn, Bo, Bp, Bq, Br, Bs, Bt, Bu, Bv, Bw, Bx, By, Bz, Ca, Cb, Cc, Cd, Ce, Cf, Cg, Ch, Ci, Cj, Ck, Cl, Cm, Cn, Co, Cp, Cq, Cr, Cs, Ct, Cu, Cv, Cw, Cx, Cy, Cz, Dd, De, Df, Dg, Dh, Di, Dj, Dk, Dl, Dm, Dn, Do, Dp, Dq, Dr, Ds, Dt, Du, Dv, Dw, Dx, Dy, Dz, Ea, Eb, Ec, Ed, Ee, Ef, Eg, Eh, Ei, Ej, Ek, El, Em, En, Eo, Ep, Eq, Er, Es, Et, Eu, Ev, Ew, Ex, Ey, Ez, Fa, Fb, Fc, Fd, Fe, Ff, Fg, Fh, Fi, Fj, Fk, Fl, Fm, Fn, Fo, Fp, Fq, Fr, Fs, Ft, Fu, Fv, Fw, Fx, Fy, Fz, Ga, Gb, Gc, Gd, Ge, Gf, Gg, Gh, Gi, Gj, Gk, Gl, Gm, Gn, Go, Gp, Gq, Gr, Gs, Gt, Gu, Gv, Gw, Gx, Gy, Gz, Ha, Hb, Hc, Hd, He, Hf, Hg, Hh, Hi, Hj, Hk, Hl, Hm, Hn, Ho, Hp, Hq, Hr, Hs, Ht, Hu, Hv, Hw, Hx, Hy, Hz, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, Im, In, Io, Ip, Iq, Ir, Is, It, Iu, Iv, Iw, Ix, Iy, Iz, Ja, Jb, Jc, Jd, Je, Jf, Jg, Jh, Ji, Jj, Jk, Jl, Jm, Jn, Jo, Jp, Jq, Jr, Js, Jt, Ju, Jv, Jw, Jx, Jy, Jz, Ka, Kb, Kc, Kd, Ke, Kf, Kg, Kh, Ki, Kj, Kk, Kl, Km, Kn, Ko, Kp, Kq, Kr, Ks, Kt, Ku, Kv, Kw, Kx, Ky, Kz, La, Lb, Lc, Ld, Le, Lf, Lg, Lh, Li, Lj, Lk, Ll, Lm, Ln, Lo, Lp, Lq, Lr, Ls, Lt, Lu, Lv, Lw, Lx, Ly, Lz, Ma, Mb, Mc, Md, Me, Mf, Mg, Mh, Mi, Mj, Mk, Ml, Mm, Mn, Mo, Mp, Mq, Mr, Ms, Mt, Mu, Mv, Mw, Mx, My, Mz, Na, Nb, Nc, Nd, Ne, Nf, Ng, Nh, Ni, Nj, Nk, Nl, Nm, Nn, No, Np, Nq, Nr, Ns, Nt, Nu, Nv, Nw, Nx, Ny, Nz, Oa, Ob, Oc, Od, Oe, Of, Og, Oh, Oi, Oj, Ok, Ol, Om, On, Oo, Op, Oq, Or, Os, Ot, Ou, Ov, Ow, Ox, Oy, Oz, Pa, Pb, Pc, Pd, Pe, Pf, Pg, Ph, Pi, Pj, Pk, Pl, Pm, Pn, Po, Pp, Pq, Pr, Ps, Pt, Pu, Pv, Pw, Px, Py, Pz, Qa, Qb, Qc, Qd, Qe, Qf, Qg, Qh, Qi, Qj, Qk, Ql, Qm, Qn, Qo, Qp, Qq, Qr, Qs, Qt, Qu, Qv, Qw, Qx, Qy, Qz, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rl, Rm, Rn, Ro, Rp, Rq, Rr, Rs, Rt, Ru, Rv, Rw, Rx, Ry, Rz, Sa, Sb, Sc, Sd, Se, Sf, Sg, Sh, Si, Sj, Sk, Sl, Sm, Sn, So, Sp, Sq, Sr, Ss, St, Su, Sv, Sw, Sx, Sy, Sz, Ta, Tb, Tc, Td, Te, Tf, Tg, Th, Ti, Tj, Tk, Tl, Tm, Tn, To, Tp, Tq, Tr, Ts, Tu, Tv, Tw, Tx, Ty, Tz, Ua, Ub, Uc, Ud, Ue, Uf, Ug, Uh, Ui, Uj, Uk, Ul, Um, Un, Uo, Up, Uq, Ur, Us, Ut, Uv, Uw, Ux, Uy, Uz, Va, Vb, Vc, Vd, Ve, Vf, Vg, Vh, Vi, Vj, Vk, Vl, Vm, Vn, Vo, Vp, Vq, Vr, Vs, Vt, Vu, Vv, Vw, Vx, Vy, Vz, Wd, We, Wf, Wg, Wh, Wi, Wj, Wk, Wl, Wm, Wn, Wo, Wp, Wq, Wr, Ws, Wt, Wu, Wv, Ww, Wx, Wy, Wz, Xa, Xb, Xc, Xd, Xe, Xf, Xg, Xh, Xi, Xj, Xk, Xl, Xm, Xn, Xo, Xp, Xq, Xr, Xs, Xt, Xu, Xv, Xw, Xx, Xy, Xz, Ya, Yb, Yc, Yd, Ye, Yf, Yg, Yh, Yi, Yj, Yk, Yl, Ym, Yn, Yo, Yp, Yq, Yr, Ys, Yt, Yu, Yv, Yw, Yx, Yy, Yz, Za, Zb, Zc, Zd, Ze, Zf, Zg, Zh, Zi, Zj, Zk, Zl, Zm, Zn, Zo, Zp, Zq, Zr, Zs, Zt, Zu, Zv, Zw, Zx, Zy, Zz				



OTHER SOURCE(S):
 M38BNT 145:273649

111 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)
 NO 907145-01-1 CAPLUS
 NO 16-Pyrrole-2-carboxamide, 3,4-dichloro-5-methyl-8-[(3,4)-3-(2-thiazolylmethoxy)-4-piperidinyl]-, rel- (CA INDEX NAME)
 Relative stereochemistry.



OS CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THIS FORMAT

111 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)
 02




AB Title compo. I [K] = independently (un)substituted R, R₂, halo, CH, alk(en)yl, etc.; R₃ = (un)substituted R, R₂, CH, halo, CH, CH=CH and derivative, W = a direct bond, NH and derivative, CH and derivative, X = a direct bond, XH₂, CO, SO₂, A = carbocyclyl, heterocyclyl with provision 14,
 R₅ = substituents on C and independently selected from halo, NO₂, CH, CH₂, NH₂, CO₂R, etc.; p = 1-4; w = 0-4; and their pharmacologically acceptable salts)
 For example, II was prepared, in 3 steps, from Me
 4-[(1-methyl-1-phenylethyl)amino]-2-[(methythio)-1,3-thiazole-5-carboxylate (preparation given)] and
 6-(4-chloro-1-[1-methoxyphenyl]idino)-4-yl]-5-methyl-18-pyrroline-2-carboxamide (preparation given). I generally displayed an
 1050 value < 20 μg/ml for the inhibition of DNA gyrase B ATPase activity using an ammonium sulfate/alkaline green-based phosphate detection assay. It had a min. inhibitory concentration of 0.15 μg/ml against
 IT 907145-01-1
 R1a RCT (Reactant); R2M (Synthetic preparation); R2EP (Preparation); R2CT (Reactant or reagent)
 (Intermediate preparation of piperidines as antibacterial agents)

111 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STM
 ACCESSION NUMBER: 2004115248 CAPLUS
 DOCUMENT NUMBER: 144:23066
 TITLE: Preparation of cyclic aminoarborescic acid derivatives
 INVENTOR(S):
 Numa, Masahiko Takano, Taro Yumoto, Kazuhiko Shimozaki, Takahiro Inoue, Shigeki Murakami, Ryo Ryojin Pharmaceutical Co., Ltd., Japan
 PATENT ASSIGNER(S):
 SOURCE: PCT Int. Appl., 244 pp.
 COBEN P10002
 DOCUMENT TYPE:
 LANGUAGE:
 FAMILY ACC. NUM. COUNT: 1
 PRIORITY INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 000601667	A3	00060216	WO 2005-0914718	20050811
Wt At, Ag, Al, An, Ar, As, Au, Ba, Bb, Bc, Bd, Be, Bf, Bg, Bh, Bi, Bj, Bk, Bl, Bm, Bn, Bo, Bp, Bq, Br, Bs, Bt, Bu, Bv, Bw, Bx, By, Bz, Ca, Cb, Cc, Cd, Ce, Cf, Cg, Ch, Ci, Cj, Ck, Cl, Cm, Cn, Co, Cp, Cq, Cr, Cs, Ct, Cu, Cv, Cw, Cx, Cy, Cz, Dd, De, Df, Dg, Dh, Di, Dj, Dk, Dl, Dm, Dn, Do, Dp, Dq, Dr, Ds, Dt, Du, Dv, Dw, Dx, Dy, Dz, Ea, Eb, Ec, Ed, Ee, Ef, Eg, Eh, Ei, Ej, Ek, El, Em, En, Eo, Ep, Eq, Er, Es, Et, Eu, Ev, Ew, Ex, Ey, Ez, Fa, Fb, Fc, Fd, Fe, Ff, Fg, Fh, Fi, Fj, Fk, Fl, Fm, Fn, Fo, Fp, Fq, Fr, Fs, Ft, Fu, Fv, Fw, Fx, Fy, Fz, Ga, Gb, Gc, Gd, Ge, Gf, Gg, Gh, Gi, Gj, Gk, Gl, Gm, Gn, Go, Gp, Gq, Gr, Gs, Gt, Gu, Gv, Gw, Gx, Gy, Gz, Ha, Hb, Hc, Hd, He, Hf, Hg, Hh, Hi, Hj, Hk, Hl, Hm, Hn, Ho, Hp, Hq, Hr, Hs, Ht, Hu, Hv, Hw, Hx, Hy, Hz, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, Im, In, Io, Ip, Iq, Ir, Is, It, Iu, Iv, Iw, Ix, Iy, Iz, Ja, Jb, Jc, Jd, Je, Jf, Jg, Jh, Ji, Jj, Jk, Jl, Jm, Jn, Jo, Jp, Jq, Jr, Js, Jt, Ju, Jv, Jw, Jx, Jy, Jz, Ka, Kb, Kc, Kd, Ke, Kf, Kg, Kh, Ki, Kj, Kk, Kl, Km, Kn, Ko, Kp, Kq, Kr, Ks, Kt, Ku, Kv, Kw, Kx, Ky, Kz, La, Lb, Lc, Ld, Le, Lf, Lg, Lh, Li, Lj, Lk, Ll, Lm, Ln, Lo, Lp, Lq, Lr, Ls, Lt, Lu, Lv, Lw, Lx, Ly, Lz, Ma, Mb, Mc, Md, Me, Mf, Mg, Mh, Mi, Mj, Mk, Ml, Mm, Mn, Mo, Mp, Mq, Mr, Ms, Mt, Mu, Mv, Mw, Mx, My, Mz, Na, Nb, Nc, Nd, Ne, Nf, Ng, Nh, Ni, Nj, Nk, Nl, Nm, Nn, No, Np, Nq, Nr, Ns, Nt, Nu, Nv, Nw, Nx, Ny, Nz, Oa, Ob, Oc, Od, Oe, Of, Og, Oh, Oi, Oj, Ok, Ol, Om, On, Oo, Op, Oq, Or, Os, Ot, Ou, Ov, Ow, Ox, Oy, Oz, Pa, Pb, Pc, Pd, Pe, Pf, Pg, Ph, Pi, Pj, Pk, Pl, Pm, Pn, Po, Pp, Pq, Pr, Ps, Pt, Pu, Pv, Pw, Px, Py, Pz, Qa, Qb, Qc, Qd, Qe, Qf, Qg, Qh, Qi, Qj, Qk, Ql, Qm, Qn, Qo, Qp, Qq, Qr, Qs, Qt, Qu, Qv, Qw, Qx, Qy, Qz, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rl, Rm, Rn, Ro, Rp, Rq, Rr, Rs, Rt, Ru, Rv, Rw, Rx, Ry, Rz, Sa, Sb, Sc, Sd, Se, Sf, Sg, Sh, Si, Sj, Sk, Sl, Sm, Sn, So, Sp, Sq, Sr, Ss, St, Su, Sv, Sw, Sx, Sy, Sz, Ta, Tb, Tc, Td, Te, Tf, Tg, Th, Ti, Tj, Tk, Tl, Tm, Tn, To, Tp, Tq, Tr, Ts, Tu, Tv, Tw, Tx, Ty, Tz, Ua, Ub, Uc, Ud, Ue, Uf, Ug, Uh, Ui, Uj, Uk, Ul, Um, Un, Uo, Up, Uq, Ur, Us, Ut, Uv, Uw, Ux, Uy, Uz, Va, Vb, Vc, Vd, Ve, Vf, Vg, Vh, Vi, Vj, Vk, Vl, Vm, Vn, Vo, Vp, Vq, Vr, Vs, Vt, Vu, Vv, Vw, Vx, Vy, Vz, Wd, We, Wf, Wg, Wh, Wi, Wj, Wk, Wl, Wm, Wn, Wo, Wp, Wq, Wr, Ws, Wt, Wu, Wv, Ww, Wx, Wy, Wz, Xa, Xb, Xc, Xd, Xe, Xf, Xg, Xh, Xi, Xj, Xk, Xl, Xm, Xn, Xo, Xp, Xq, Xr, Xs, Xt, Xu, Xv, Xw, Xx, Xy, Xz, Ya, Yb, Yc, Yd, Ye, Yf, Yg, Yh, Yi, Yj, Yk, Yl, Ym, Yn, Yo, Yp, Yq, Yr, Ys, Yt, Yu, Yv, Yw, Yx, Yy, Yz, Za, Zb, Zc, Zd, Ze, Zf, Zg, Zh, Zi, Zj, Zk, Zl, Zm, Zn, Zo, Zp, Zq, Zr, Zs, Zt, Zu, Zv, Zw, Zx, Zy, Zz				

ASSIGNMENT HISTORY FOR OS PATENT AVAILABLE IN L505 DISPLAY FORMAT
 OTHER SOURCE(S):
 M38BNT 144:230646
 02

111 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)



AS Title compds. 1 [Ar = (un)substituted aryl, (un)substituted heterocycl, etc.; Y = alkylene, alkenylene, alkynylene, etc.; R = O, S, =C(SH)-; n = 0-7; X = H, halo, optionally substituted alkyl with halo, etc.; R = H, alkyl, -C(SH)- is substituted at n- or n-position of CO group to ring M] were prepared for example, reaction of compound II [R1 = R, n = 0, prepared from 2-[4-(chlorophenyl)-4-methylthiazole-5-carboxylic acid in 2 steps, with 2-fluorobenzoic acid Me ester followed by hydrolysis afforded compound II [R1 = 2-carboxyphenyl]. In PPAase transcription activation assays, the EC50 value of compound II [R1 = 2-carboxyphenyl] was 0.045 nMol/L. Compds. 1 are claimed useful for the treatment of arteriosclerosis, diabetes, etc.

IT 876147-41-47 876148-44-42
R1 RCT (Reactant) SYN (Synthetic preparation) PREP (Preparation) RACT (Reactant or reagent)
for preparation of cyclic antihydrobenzoic acid deriva. as PPAase agonists
for treatment of arteriosclerosis, diabetes, etc.)


RI 876147-41-4 CAPLUS
CI Piperidine, 3-[12-(4-chlorophenyl)-4-methyl-5-thiazolyl]methoxy]- (CA INDEX NAME)

111 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)



RI 876148-44-4 CAPLUS
CI Piperidine, 3-[12-(4-chlorophenyl)-4-methyl-5-thiazolyl]methoxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



111 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)

ACCESSION NUMBER: 2009170486 CAPLUS
DOCUMENT NUMBER: 142176825
TITLE: Preparation of heterocyclic compounds, their use as tyrosine kinase inhibitors and antitumor agents, and treatment of tumor with (products of the compounds Inoue, Shunshu; Tanaka, Masahiko; Yoshida, Kiyoshi; Ishikawa, Tomoyasu; Nishikawa, Yoichi; Tanaka Chemical Industries, Ltd., Japan
Jpn. Kokai Tokkyo Koho, 99 pp.
CDDEN: JF00047
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005023007	A	200505127	JP 2003-189055	20030630
PRIORITY APPL. INFO.			JP 2003-189055	20030630

OTHER SOURCE(S): MARCH 142176825
GI

111 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)




AS Title compds. 1 [ring A1, A2 = (un)substituted aromatic hydrocarbon ring, (un)substituted aromatic heterocyclic ring; R1, R2 = (un)substituted H-containing, S-containing aromatic heterocyclic ring; R1, R2 = bond, ethylene, vinylene; Y1, Y2 = bond, (un)substituted C1-3 alkylene; R1, R2 = bond, O, (un)substituted H, (un)substituted S, etc.; W = (un)substituted C1-10 alkylene, (un)substituted nonarom. hydrocarbon ring, (un)substituted nonarom. heterocyclic ring, etc.] or their salts are prepared. Thus, formation of 1,3-bis-[2-[(R1)-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-oxazol-4-yl]methoxy]-3-pentane with R0R02, R01 gave the corresponding oxime, which inhibited phosphorylation of receptor tyrosine kinase in human breast cancer cell line BT 474 with IC50 value of 8.4 nM.

IT 832710-41-77 832710-41-77
R1 RCT (Reactant) SYN (Synthetic preparation) PREP (Preparation) RACT (Reactant or reagent)
for preparation of heterocyclic compds. as tyrosine kinase inhibitors for treatment of tumor)

RI 832710-41-7 CAPLUS
CI Piperidine, 2-[12-[2-[(R1)-2-[4-(trifluoromethyl)phenyl]ethoxy]]-4-oxazolyl]methoxy]-, hydrochloride (1:1) (CA INDEX NAME)


Double bond geometry as above.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 188861-52-1 CAPLUS
CN Piperidine, 3-[(benzo[b]thien-5-ylmethoxy)-4-(4-fluorophenyl)]-, (7S,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.




HN 188861-55-4 CAPLUS
CN Isopropylamine, 6-[[[17R,4R)-4-(4-fluorophenyl)-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




CH 2
CHN 75-75-2
CHP C 84 O 3 S



HN 188862-59-0 CAPLUS
CN Quinolone, 2-[[[17R,4R)-4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




HN 188862-62-4 CAPLUS
CN Piperidine, 3-[(2-benzofuranyl)ethoxy]-4-(4-chlorophenyl)-, hydrochloride [1:1], (7R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


HN 188862-72-0 CAPLUS
CN Piperidine, 3-[(2,3-dihydro-3,4-benzodioxan-6-yl)methoxy]-4-(4-fluorophenyl)-, (7R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



HN 188862-74-2 CAPLUS
CN Piperidine, 3-[(5-benzofuranyl)ethoxy]-4-(4-fluorophenyl)-, (7R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.




HN 188862-46-6 CAPLUS
CN Piperidine, 3-[1,3-benzodioxol-5-ylmethoxy]-4-(4-chlorophenyl)-, (7R,4R)-rel-, methanesulfonate (1:1) (CA INDEX NAME)

CH 1

CHN 188862-45-5
CHP C19 H20 Cl N O3

Relative stereochemistry.


L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

HN 188862-62-6 CAPLUS
CN Piperidine, 3-[(benzo[b]thien-5-ylmethoxy)-4-(4-chlorophenyl)]-, hydrochloride (1:1), (7R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl


HN 188866-50-4 CAPLUS
CN 1-Butanone, 4-[[4-[(7R,4R)-3-(benzo[b]thien-5-ylmethoxy)-4-piperidinyl]phenyl]-1-phenyl]-, sel- (CA INDEX NAME)

Relative stereochemistry.

111 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RD 18875-74-3 CAPLUS
 CN Benzocyclobutol, 4-[[[13,42]-3-(benzo[b]thien-5-yl)methoxy]-4-piperidinyl]phenyl]propyl-, rel- (CA INDEX NAME)
 Relative stereochemistry.




RD 18875-64-6 CAPLUS
 CN Piperidine, 3-[[2,3-dihydro-1,4-benzodioxin-6-yl]methoxy]-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-, (1R,4R)-rel- (CA INDEX NAME)
 Relative stereochemistry.

112 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




● R,R


RD 18875-89-0 CAPLUS
 CN Quinolizine, 7-[[[13,4R]-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)
 Relative stereochemistry.




RD 18875-90-3 CAPLUS
 CN Quinolizine, 7-[[[13,4R]-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)
 Relative stereochemistry.



113 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RD 18875-04-3 CAPLUS
 CN Pyridine, 2-[[[13,4R]-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)
 Relative stereochemistry.



RD 18875-06-5 CAPLUS
 CN Piperidine, 3-[[1,3-benzodioxol-5-yl)methoxy]-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-, hydrochloride (1:1), (1R,4R)-rel- (CA INDEX NAME)
 Relative stereochemistry.


114 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RD 18875-92-4 CAPLUS
 CN Quinolizinium, 1-methyl-7-[[[13,4R]-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, chloride (1:1), rel- (CA INDEX NAME)
 Relative stereochemistry.




● Cl-

RD 18875-92-5 CAPLUS
 CN Quinolizine, 1,2,3,4-tetrahydro-1-methyl-7-[[[13,4R]-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)
 Relative stereochemistry.




RD 18875-93-6 CAPLUS
 CN Isoquinoline, 6-[[[13,4R]-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)
 Relative stereochemistry.

111 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 188875-94-7 CAPLUS
 CN Quinoline, 1,2,3,4-tetrahydro-6-[[[(3R,4R)-4-{4-[3-(4-methoxyphenyl)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



HN 188875-95-8 CAPLUS
 CN Quinoline, 7-[[[(3R,4R)-4-{4-[3-{[2-methoxyphenyl]methoxy]propoxy]phenyl}-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

111 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 188875-96-9 CAPLUS
 CN 18-Benzazepine, 6-[[[(3R,4R)-4-{4-[3-(4-methoxyphenyl)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



HN 188875-97-0 CAPLUS
 CN Quinoline, 7-[[[(3R,4R)-4-{4-[4-[3-{[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, 1-oxide, rel- (CA INDEX NAME)


Relative stereochemistry.

111 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 188875-98-1 CAPLUS
 CN 2-[(1R)-Quinoxaline, 7-[[[(3R,4R)-4-{4-[3-{[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



HN 188875-99-2 CAPLUS
 CN Isoquinoline, 7-[[[(3R,4R)-4-{4-[3-{[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

111 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 188876-00-8 CAPLUS
 CN Quinoline, 1,2,3,4-tetrahydro-7-[[[(3R,4R)-4-{4-[3-{[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



HN 188876-01-9 CAPLUS
 CN Quinoxaline, 6-[[[(3R,4R)-4-{4-[3-{[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



FN 188881-00-3 CAPLUS
CN Quinazolinone, 7-[[[(1R,4R)-4-[4-[13-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



FN 188881-00-5 CAPLUS
CN 2,1,8-Quinoxaline, 7-[[[(1R,4R)-4-[4-[13-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




IT 188881-00-7 Piperidine,
3-[[[(1R,4R)-4-[4-[13-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, trans-
188881-00-7, trans- 188881-00-7, Piperidine,
3-[[[(1R,4R)-4-[4-[13-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel-
E1, RCT (Seamless) SM (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

[Methods of treating or preventing Alzheimer's and other diseases]

using 4-ary-3-methylpiperidines and -azabicyclooctanes)

FN 188881-00-7 CAPLUS
CN Piperidine, 3-[[[(1R,4R)-4-[4-[13-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



FN 188881-00-1 CAPLUS
CN Piperidine, 3-[[[(1R,4R)-4-[4-[13-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



FN 188881-00-4 CAPLUS
CN Isoquinoline, 7-[[[(1R,4R)-4-[4-[13-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



FN 188881-00-9 CAPLUS
CN Quinoxaline, 2,2,3,4-tetrahydro-7-[[[(1R,4R)-4-[4-[13-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




FN 188881-00-5 CAPLUS
CN Piperidine, 3-[[[(1R,4R)-4-[4-[13-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



FN 188881-00-9 CAPLUS
CN Pyridine, 2-[[[(1R,4R)-4-[4-[13-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




IT 188881-00-9 Pyridine, 3-[[[(1R,4R)-4-[4-[13-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)
[Methods of treating or preventing Alzheimer's and other diseases]

using

111 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS ON SYN (Continued)
 4-aryl-2-arylpyrrolidine and -azabicyclooctanes)
 RD 18881-44-0 CAPLUS
 CN Pyridine, 3-[[1(1H,4H)-6-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, dihydrochloride, rel- (19C) (CA INDEX NAME)

Relative stereochemistry.



●, R1

ON-CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

111 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2009 ACS ON SYN (Continued)
 ACCESSION NUMBER: 2001.51692E CAPLUS
 DOCUMENT NUMBER: 135.11358E


TITLE: Piperidine renin inhibitors: From leads to drug candidates
 AUTHOR(S): Machi, H.; P.; Elmagli, A.; Ritter, B.; Bohner-Lang, V.; Remy, V.; Bur, D.; Ocasio, Ph.; Clozel, J. F.; D'Arcy, A.; Desbailly, M.; Fieckel, W.; Fony, Ch.; Forscheur, J.; Giller, T.; Gruninger, F.; Guesni, A.; Guller, R.; Hartung, T.; Kirth, G.; Jentz, Ch.; Kirschhammer, R.; Lave, T.; Lohr, R.; Luft, F. C.; Merz, E. M.; Heller, B. H.; Muller, M.; Montavon, F.; Oefner, Ch.; Qiu, C.; Reibel, A. J.

KEY: Kirschhammer, R.; Lave, T.; Lohr, R.; Luft, F. C.; Merz, E. M.; Heller, B. H.; Muller, M.; Montavon, F.; Oefner, Ch.; Qiu, C.; Reibel, A. J.
 SEARCHED: P.; Schuster, M.; Schuster, M.; Schmid, F.; Stadler, H.; Teuber, A.; Voldenauer, O.; Voss, E.; Willems, P.; Wiegand-Chen, R.; Wilsch, M.; Wurtl, W.; Zell, M.; Zell, R.
 CORPORATE SOURCE: Pharma Research, F. Hoffmann-La Roche Ltd, Basel, CH-4000, Switz.
 SOURCE: Farmaco (2001), 56(1-2), 23-27
 COUNTRY: FR;FR; JPRS: 0014-572
 PUBLISHER: Elsevier Science S.A.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB: Non-peptidomimetic renin inhibitors of the piperidine type represent a novel structural class of compounds. potentially free of the drawbacks seen with peptidomimetic compounds. so far. Synthetic optimization in two structural series focusing on improvement of potency, as well as on pharmacokinetic properties and metabolic stability, has led to the identification of two candidate compounds. Both display potent and long-lasting blood pressure lowering effects in conscious sodium-depleted, normotensive monkeys and double transgenic rats harboring both the human angiotensinogen and the human renin genes. In addition, one of compounds normalizes albuminuria and kidney tissue damage in these rats when given over a period of 4 wk. These data suggest that treatment of chronic renal failure patients with a renin inhibitor might result in a significant improvement of the disease status.

IT 304025-53-49
 RI: RAC (Biological activity or effector, except address); BPO (Biological study, unclassified); PEP (Preparation); PEP (Synthetic preparation); THU (Therapeutic use); BPO (Biological study); PEP (Preparation); VES (Vesicle)
 (Piperidine renin inhibitors: From leads to drug candidates)
 RD 18881-44-0 CAPLUS
 CN Aminoalcohol, 1,2,3,4-tetrahydro-7-[[1(1H,4H)-6-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, dihydrochloride, rel- (19C) (CA INDEX NAME)
 Absolute stereochemistry.

111 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS ON SYN (Continued)


RD 18881-10-9 304025-56-7 304025-57-8
 304025-62-5 304025-63-6 304025-70-5
 304025-71-6 304025-73-8
 RI: RAC (Biological activity or effector, except address); BPO (Biological study, unclassified); THU (Therapeutic use); BPO (Biological study); PEP (Preparation); VES (Vesicle)
 (Piperidine renin inhibitors: From leads to drug candidates)
 RD 18881-10-9 CAPLUS
 CN Quinolizidine, 1,2,3,4-tetrahydro-7-[[1(1H,4H)-6-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, dihydrochloride, rel- (19C) (CA INDEX NAME)
 Absolute stereochemistry.



RD 18881-10-9 CAPLUS
 CN Quinolizidine, 1,2,3,4-tetrahydro-7-[[1(1H,4H)-6-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, dihydrochloride, rel- (19C) (CA INDEX NAME)
 Absolute stereochemistry.


111 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2009 ACS ON SYN (Continued)

RD 18881-10-9 CAPLUS
 CN Quinolizidine, 1,2,3,4-tetrahydro-7-[[1(1H,4H)-6-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, dihydrochloride, rel- (19C) (CA INDEX NAME)
 Absolute stereochemistry.




RD 18881-10-9 CAPLUS
 CN Quinolizidine, 1,2,3,4-tetrahydro-7-[[1(1H,4H)-6-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, dihydrochloride, rel- (19C) (CA INDEX NAME)
 Absolute stereochemistry.

L11 ANIMELE 12 OF 17 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)



202 304025-65-8 CAPLOS
CN Quazoline,
2,3,4-tetrahydro-2-[2-(1H-imidazol-3-yl)ethyl]-7-[[[(2R,4R)-4-[4-(3-{[(2-methoxyphenyl)methoxy]propoxy}phenyl)-3-piperidinyl]oxy)methyl]-


Absolute stereochemistry.



J20 304025-44-9 CAPLUS
 C20 Quinoline, 1,2,3,4-tetrahydro-7-[[[3R,6R)-4-[4-[3-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-2-(3-methoxybenzyl)- (CA INDEX NAME)


Absolute stereochemistry.

111 ANSWER 12 OF 17 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)



720 304023-69-2 CAPLOS
 CN QM001156
 1,2,3,4-tetrahydro-1-(2-methoxyethyl)-7-[[[3R,4R)-4-{4-[3-{[2-methoxyphenyl]methoxy}propoxy]phenyl}-3-piperidinyl]oxy)methyl]- (CN
 INDEX NAME)


Absolute stereochemistry.



C29 Methazurilofonamide, N-[2-[3,4-dihydro-7-[[[3R,4R]-4-[4-[2-[[2-(
nethoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-2 (2H)-
quinoxalyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 12 OF 17 CAPLAS COPYRIGHT 2009 ACS on 5TH (Continued)



IN 304025-67-0 CAPLOS
CN 1(2H)-Quinolinetetramine, 3,4-dihydro-7-[[[3,4,4b)-4-{4-[3-{(2-nethoxyphenyl)ethoxy]propoxy}phenyl)-3-piperidinyl]oxy]methyl)- (CA
INDEX NAME)

Absolute stereochemistry.




```

NN 304025-68-1 CAPLUS
CN 1(2H)-Quinolineacetonitrile, 3,4-dihydro-7-[[[3R,4R)-4-{4-[3-{[2-
net hoxyphe nyl]net hox y]propoxy]phenyl]-3-piper idinyl]oxy]methyl)- (CA
INDEX NAME)

```


Absolute stereochemistry.

L11 ANSWER 12 OF 17 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)



HN 304025-71-6 CAPLUS
 CN Sulfamide, N-[2-{3,4-dihydro-7-[[[3R,4R]-4-{4-[3-{[2-methoxyphenyl]methoxy}propoxy]phenyl]-3-piperidinyl]oxy]methyl}-1(2H)-quinolinyl]ethyl- (CA INDEX NAME)

Absolute stereochemistry




```

IN  004025-72-7  CAPLUS
CN  1(2N)-Quinolineethanamine, 3,4-dihydro-9-[[[3R,4R]-4-{4-[3-{[2-
    methoxyphenyl]methoxy]propoxy}phenyl]-2-piperidinyl]oxy]methyl]-N,N-
    dimethyl- (CA INDEX NAME)

```


Absolute stereochemistry

111 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



30 304025-71-8 CAPLUS
 CN 1244, 3-[2-[3,4-dihydro-7-[[[13R,4R]-6-[4-[3-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2R)-quinolinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



30 304025-74-3 CAPLUS
 CN Acetanilide, N-[2-[3,4-dihydro-7-[[[13R,4R]-6-[4-[3-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2R)-quinolinyl]ethyl]-2,4,5-trifluoro- (CA INDEX NAME)


Absolute stereochemistry.

111 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



30 304025-77-2 CAPLUS
 CN 2-[2R]-Quinolinesuccinic acid, 3,4-dihydro-7-[[[13R,4R]-6-[4-[3-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



30 304025-78-3 CAPLUS
 CN 2-[2R]-Quinolinesuccinamide, 3,4-dihydro-7-[[[13R,4R]-6-[4-[3-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

111 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



30 304025-75-0 CAPLUS
 CN Quinolizine, 7-[[[13R,4R]-6-[4-[3-[[2-cyclopropyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1,2,3,4-tetrahydro-1-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



30 304025-76-1 CAPLUS
 CN Quinolizine, 1,2,3,4-tetrahydro-1-(3-methoxypropyl)-7-[[[13R,4R]-6-[4-[3-[[2,2,2-trifluoroethyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

111 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



30 304025-79-4 CAPLUS
 CN 2-[1R]-Quinolinesuccinic acid, 3,4-dihydro-7-[[[13R,4R]-6-[4-[3-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



30 304025-80-7 CAPLUS
 CN 1-[1R]-Quinolinesuccinopropanoic acid, 3,4-dihydro-7-[[[13R,4R]-6-[4-[3-[[2-methoxyphenyl]methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

111 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RD 188862-59-1 CAPLUS
CN Piperidine, 3-[5-(benzo[*b*]furanylmethoxy)-4-(4-chlorophenyl)-, (3*R*,4*R*)-*rel*- (CA INDEX NAME)

Relative stereochemistry.



RD 188862-61-5 CAPLUS
CN Piperidine, 3-[benzo[*b*]thiazol-2-ylmethoxy]-4-(4-chlorophenyl)-, (3*R*,4*R*)-*rel*- (CA INDEX NAME)

Relative stereochemistry.




RD 188862-65-9 CAPLUS
CN Pyridine, 3-[[[(3*R*,4*R*)-4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, *rel*-

112 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


study); PREP (Preparation); USER (User)
[Deriv. of piperidine and azabicyclooctane derivs. as renin inhibitors]
RD 188862-51-0 CAPLUS
CN Quinoxaline, 2-[[[(3*R*,4*R*)-4-(4-fluorophenyl)-3-piperidinyl]oxy]methyl]-4-methoxy-, *rel*- (CA INDEX NAME)

Relative stereochemistry.



RD 188862-52-1 CAPLUS
CN Piperidine, 3-[benzo[*b*]thiazol-5-ylmethoxy]-4-(4-fluorophenyl)-, (3*R*,4*R*)-*rel*- (CA INDEX NAME)

Relative stereochemistry.




RD 188862-55-4 CAPLUS
CN Isoquinoline, 6-[[[(3*R*,4*R*)-4-(4-fluorophenyl)-3-piperidinyl]oxy]methyl]-, *rel*- (CA INDEX NAME)

Relative stereochemistry.


113 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

(CA INDEX NAME)
Relative stereochemistry.



IT 188862-66-0P
RI: SPH (Synthetic preparation); PREP (Preparation)
[Preparation of piperidine and azabicyclooctane derivs. as renin inhibitors]
RD 188862-66-0 CAPLUS
CN Pyridine, 3-[[[(3*R*,4*R*)-4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, dihydrochloride, *rel*- (3*R*1) (CA INDEX NAME)


Relative stereochemistry.



● C HCl


IT 188862-51-0P 188862-52-1P 188862-55-4P
188862-59-0P 188862-61-5P 188862-65-9P
188862-58-0P 188862-60-4P 188862-62-4P
188866-50-4P 188866-74-2P 188870-64-6P
188873-04-3P 188873-06-5P 188875-09-0P
188875-06-1P 188875-31-4P 188875-32-5P
188875-33-6P 188875-34-7P 188875-36-9P
188875-37-0P 188876-63-9P 188881-62-9P
188881-08-5P 188881-09-6P 188881-10-9P
RI: SPH (Synthetic preparation); THO (Therapeutic use); ROL (Biological

113 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RD 188862-32-0 CAPLUS
CN Piperidine, 3-[1,2-dihydro-3,4-benzodioxin-6-ylmethoxy]-4-(4-chlorophenyl)-, (3*R*,4*R*)-*rel*- (CA INDEX NAME)

Relative stereochemistry.



RD 188862-34-2 CAPLUS
CN Piperidine, 3-[5-benzofuranylmethoxy]-4-(4-fluorophenyl)-, (3*R*,4*R*)-*rel*- (CA INDEX NAME)

Relative stereochemistry.




RD 188862-46-4 CAPLUS
CN Piperidine, 3-[1,2-benzodioxol-5-ylmethoxy]-4-(4-chlorophenyl)-, (3*R*,4*R*)-*rel*-, methanesulfonate (1:1) (CA INDEX NAME)

CN 1

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 CNF C19 R22 C1 N O3

Relative stereochemistry.




CN 2

CN 15-15-2
 CNF C 84 O3 S




RN 188862-53-0 CAPLUS
 CN Quinolizidine, 2-[[[1(3R,4R)-4-(4-chlorophenyl)-3-piperidyl]oxy]methyl]-,
 sel- (CA INDEX NAME)

Relative stereochemistry.




RN 188862-60-4 CAPLUS
 CN Piperidine, 3-[2-benzofuranylmethoxy]-4-(4-chlorophenyl)-, hydrochloride
 (1:1), (3R,4R)-sel- (CA INDEX NAME)

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 188866-74-2 CAPLUS
 CN Benzenemethanol, α-[3-[[[1(3R,4R)-3-(benzo[h]thien-5-ylmethoxy)-4-piperidyl]phenoxy]propyl]-, sel- (CA INDEX NAME)

Relative stereochemistry.




RN 188870-64-6 CAPLUS
 CN Piperidine, 3-[[[1(3R,4R)-4-(4-chlorophenyl)-3-piperidyl]phenoxy]propyl]-, sel- (CA INDEX NAME)

Relative stereochemistry.



RN 188873-04-3 CAPLUS
 CN Pyridine, 3-[[[1(3R,4R)-4-(4-[3-(phenylmethoxy)propoxy]phenyl]-3-


L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 Relative stereochemistry.



● HCl

RN 188862-62-6 CAPLUS
 CN Piperidine, 3-(benzo[h]thien-2-ylmethoxy)-4-(4-chlorophenyl)-,
 hydrochloride (1:1), (3R,4R)-sel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 188866-50-4 CAPLUS
 CN 1-Butanone, 4-[[[1(3R,4R)-3-(benzo[h]thien-5-ylmethoxy)-4-piperidyl]phenoxy]-1-phenyl-, sel- (CA INDEX NAME)

Relative stereochemistry.


L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 piperidyl]oxy]methyl]-, sel- (CA INDEX NAME)

Relative stereochemistry.



RN 188873-06-5 CAPLUS
 CN Piperidine, 3-[[[1(3R,4R)-3-(benzodioxol-5-ylmethoxy)-4-[3-(phenylmethoxy)propoxy]phenyl]-, hydrochloride (1:1), (3R,4R)-sel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 188875-69-0 CAPLUS
 CN Quinolizidine, 7-[[[1(3R,4R)-4-(4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidyl]oxy]methyl]-, sel- (CA INDEX NAME)


Relative stereochemistry.

111 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RU 188875-90-3 CAPLUS
 CN Quinolizine, 1,2,3,4-tetrahydro-7-[[1,3,4,6,8-pentacyclo[3.3.1.0.0.0.0]hepta-2,5-dien-1-yl]oxy]methyl-1-, sel- (CA INDEX NAME)
 NAME


Relative stereochemistry.



RU 188875-91-4 CAPLUS
 CN Quinolizine, 1,2,3,4-tetrahydro-7-[[1,3,4,6,8-pentacyclo[3.3.1.0.0.0.0]hepta-2,5-dien-1-yl]oxy]methyl-1-, sel- (CA INDEX NAME)
 NAME


Relative stereochemistry.

112 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RU 188875-92-5 CAPLUS
 CN Quinolizine, 1,2,3,4-tetrahydro-7-[[1,3,4,6,8-pentacyclo[3.3.1.0.0.0.0]hepta-2,5-dien-1-yl]oxy]methyl-1-, sel- (CA INDEX NAME)
 NAME


Relative stereochemistry.



RU 188875-93-6 CAPLUS
 CN Quinolizine, 1,2,3,4-tetrahydro-7-[[1,3,4,6,8-pentacyclo[3.3.1.0.0.0.0]hepta-2,5-dien-1-yl]oxy]methyl-1-, sel- (CA INDEX NAME)
 NAME


Relative stereochemistry.

113 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RU 188875-94-7 CAPLUS
 CN Quinolizine, 1,2,3,4-tetrahydro-6-[[1,3,4,6,8-pentacyclo[3.3.1.0.0.0.0]hepta-2,5-dien-1-yl]oxy]methyl-1-, sel- (CA INDEX NAME)
 NAME

Relative stereochemistry.



RU 188875-96-9 CAPLUS
 CN Quinolizine, 1,2,3,4-tetrahydro-6-[[1,3,4,6,8-pentacyclo[3.3.1.0.0.0.0]hepta-2,5-dien-1-yl]oxy]methyl-1-, sel- (CA INDEX NAME)
 NAME


Relative stereochemistry.



RU 188875-97-0 CAPLUS
 CN Quinolizine, 7-[[1,3,4,6,8-pentacyclo[3.3.1.0.0.0.0]hepta-2,5-dien-1-yl]oxy]methyl-1-, sel- (CA INDEX NAME)
 NAME


Habe

114 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RU 188876-01-9 CAPLUS
 CN Quinolizine, 6-[[1,3,4,6,8-pentacyclo[3.3.1.0.0.0.0]hepta-2,5-dien-1-yl]oxy]methyl-1-, sel- (CA INDEX NAME)
 NAME

Relative stereochemistry.



RU 188881-02-9 CAPLUS
 CN Quinolizine, 7-[[1,3,4,6,8-pentacyclo[3.3.1.0.0.0.0]hepta-2,5-dien-1-yl]oxy]methyl-1-, sel- (CA INDEX NAME)
 NAME

Absolute stereochemistry.

=> d sca 110

[illegible][illegible]

[illegible]

tandemly as well as sequentially.

[illegible]

yellowish brown; hexyl hexanoate. 957276-71-2B. Methyl

[illegible]

1,1,1,3,3,3-hexafluoro-4-(4-{3-[2-methoxyethoxy]propoxy}phenyl)piperidinemethanol-2-yl-1-[1-methoxy-2-methyl-2H-indol-3-yl]indole

[illegible]

2-0760 851213-84-07, 7-11113K, 4K)-4-14-14-12-

[illegible][illegible][illegible][illegible]

[illegible][illegible][illegible][illegible]

Habt.e

[illegible]

[illegible][illegible][illegible]

[illegible][illegible]

difluorophenyl)propyl]phenyl]-3-[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-
2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-3-carboxylate 857271-53-3P,
tert-butyl-3(3R,4R)-4-[4-(3-[2,4-difluorophenyl)propyl]phenyl]-3-
hydroxypiperidine-1-carboxylate 857271-55-5P,
6-[[1(3R,4R)-4-[4-(3-[2,4-difluorophenyl)propyl]phenyl]piperidin-3-
ylloxy)methyl]-4-(3-methoxypropyl)-6H-benzo[1,4]oxazin-3-one
857271-56-6P, tert-butyl-3(3R,4R)-6-[4-(3-[2,4-

```

difluorophenyl]oxy]phenyl]-3-[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-
2H-benz[1,4]oxazin-4-yl]methoxy]phenyl]-1-carboxylate 85727-57-TP,
text=Butyl [1R,4R]-4-[4-(3-[2,3-difluorophenyl]oxy]phenyl]-2-
hydroxyphenyl]-1-carboxylate 85727-58-8P,
1-[3-(3-oxopropoxy)-2,3-difluorobenzene 85727-60-2P,
1-[1R,4R]-4-[4-(3-[4-(3-methoxypropyl]oxy]phenyl]piperidin-3-
yl]oxy]methyl]-4-(3-methoxypropyl)-6-ethyl-2,4,4a,6-tetrahydro-3H-
85727-61-3P, text=Butyl
[1R,4R]-4-[4-(3-[4-(4-fluorophenyl]oxy]phenyl)]piperidin-3-

```

```
y[1]:methoxy|pipe|idine-1-carboxylate 857277-62-4P, tert-Butyl
|3R,4R|-4-[[3-4-(2-fluorophenoxy)propoxy]phenyl]-2-hydroxy|paper|idine-1-
carboxylate 857277-64-6P,
6-[[[(3R,4R)-6-[[4-[[3-12-(6-fluorohexyloxy)propoxy]propoxy]phenyl]piperidin-3-
yl]oxy]methyl]-6-[[3-methoxypropyl]-6-oxo-1,2,4-oxadiazin-3-one
857277-63-7P, tert-Butyl (3R,4R)-4-[[4-[[3-12-(6-
```

~~di(1-urethaneoxy)propylphenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4'-oxazin-6-yl]methoxy]piperidine-1-carboxylate~~ 857277-66-8P,
~~tert-butyl-[(3R,4S)-4-[[4-(3-(2,6-di(1-urethaneoxy)propyl)propyl)-3-hydroxypiperidine-1-carboxylate~~ 857277-67-9P,
~~2-(3-(2-urethaneoxy)propyl)-3-di(1-urethaneoxy)benzene~~ 857277-69-3P,
~~6-[[[(1R,4S)-4-[[4-(3-[[3-(4-di(1-urethaneoxy)propyl)phenyl]piperidin-3-ylmethoxy]methyl)-4-(3-methoxypropyl)-6H-benzo[1,4'-oxazin-3-one~~

COC(=O)C1CCN(C1Cc2ccccc2)c3ccccc3 857277-71-5P,
di[fluorophenox]ypropoxy[phenyl]-3-[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-
2H-benzo[1,4][oxazin-6-yl]methoxy]piperidine-1-carboxylate 857277-71-5P,

```

L10  2  ANSWERS  CAUSE  COPYRIGHT  2009  ACS  on  STN  (Continued)
4-Bromomethyl-1-(2-ethoxy-2-[3-methoxypropoxy]benzene  857277-12-4P,
1-Ethoxy-2-[3-methoxypropoxy]-4-methylbenzene  857277-13-5P,
1-(2-Ethoxy-5-methylphenyl)ethanone  857277-15-7P, tart-Butyl
(3R,4R)-4-[4-[3-(2-methoxybenzoyloxy)propoxy]phenyl]-3-[[1(2R)-6-(4-

```

[3R,4R]-2-[1-[(2R)-1,4-dihydro-2H-benzo[1,4]oxazin-2-yl)methoxy]-4-[4-{3-[(2-methoxybenzyl)oxy]propoxy}phenyl]piperidine-1-carboxylate 857277-16-8P, tert-Butyl

(3*H*, 4*H*)-4-[[3-(2-methoxybenzoyloxy)propoxy]phenyl]-3-[[[(2*H*)-4-(4-tolylsulfonyl)-3,4-dihydro-2*H*-benzo[1,4]oxazin-2-yl)methoxy]piperidine-1-carboxylethyl 85777-18-0P, tert-butyl
(3*H*, 4*H*)-3-[[[(2*H*)-4-(4-tolylsulfonyl)-3,4-dihydro-2*H*-benzo[1,4]oxazin-2-yl)methoxy]piperidine-1-

hydroxypropoyl-4-[4-[3-(2-methoxybenzoyloxy)propoxy]phenyl]piperidine-1-carboxylate 857277-19-3P, tert-Butyl
(3R,4R)-4-[4-[3-(2-methoxybenzoyloxy)propoxy]phenyl]-3-(1R)-oxiranemethoxypiperidine-1-carboxylate 857277-21-5P, tert-Butyl

methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857277-22-6P, N-[2-[4-Chloro-2-hydroxyphenyl]ethyl]acetamide 857277-24-6P, tert-Butyl (3R,4R)-4-[4-[2-[2-methoxybenzyl)oxy]propoxy]phenyl]-3-[1(2S)-4-(4-

carboxylate 857277-25-9P, text-Betyl

[3*R*, 4*R*]-4-[4-[3-[2-(*n*-hydroxybenzoyloxy)propoxy]phenyl]-3-[[2*S*]-4-[4-tolylsulfonyl]-3,4-dihydro-2*H*-benzo[1,4]oxazin-2-yl)methoxy]piperidine-1-carboxylate 857277-27-3*P*, test-Butyl [3*R*, 4*R*]-2-[[2*S*]-3-[[2-(fluorobenzyloxy)-4-tolylsulfonyl]amino]-2-

hydroxypropoxy)-4-[4-[3-[2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857277-28-2P, tert-Butyl (3R,4R)-4-[4-[3-[2-methoxybenzyl)oxy]propoxy]phenyl]-3-(1S)-oxiranemethoxy)piperidine-1-carboxylate 857277-30-6P,

4-[3-Methoxypropyl)- α -[1[(3R,4R)-4-[4-(3-phenoxypropoxy)phenyl]piperidin-3-yl]oxy]benzothiol]-4H-benzo[1,4]oxazin-3-one 857277-71-7P, tert-Butyl [3(R,4R)-3-[4-(3-methoxypropoxy)-3-oxo-3,4-dihydro-2H-benzol[1,4]oxazin-6-yl]methoxy]-4-[4-(3-phenoxypropoxy)piperidin-1-carboxylate 857279-33-2N, same as 857277 (3R,4R)-2-hydroxy-4,4'-bis(4-

phenoxypropoxy)methyl]piperidine-1-carboxylate 857277-35-LP, tert-Butyl
(3R,4R)-4-[4-[3-[2-(methoxybenzoyloxy)propoxy]phenyl]-3-[[[3-methoxy-2-(2-
methoxyethoxy)phenyl]methoxy]piperidine-1-carboxylate 857277-36-2P,
1-Chloromethyl-3-methoxy-2-[3-methoxyethoxy]benzene 857277-37-3P,
3-Methoxy-2-[3-methoxyethoxy]phenylmethanol 857277-39-5P, tert-Butyl

```

1.10 2 ANISERS CAPLOS COPYRIGHT 2009 ACS ON SYN (Continued)
test-Butyl [3K,4K)-4-[4-(3-[3,4-difluorophenyl]propyl)phenyl]-3-
hydroxypiperidine-1-carboxylate 857277-72-6R,
4-(3-Ethoxypropyl)-1,2-difluorobenzene 857277-74-8P,
6-[[(1K,4K)-4-[4-(3-[3,5-Difluorophenyl]propyl)phenyl]piperidin-3-
yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one
857277-75-9P, test-Butyl [3K,4K)-4-[4-(3-[3,5-

```

di(2-fluorophenoxy)propyl]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate
 RE: ECT (Reactant); SYN (Synthetic preparation); PREP (Preparation); FACT (Reactant or reagent)

and other disorders)

17 857277-76-0P, text-Butyl (3R,4R)-4-[4-[3-[3,5-difluorophenoxy]propyl]phenyl]-3-hydroxypiperidine-1-carboxylate

857277-77-1P, 1-[3-(8-methoxypropyl)-3,5-difluorobenzene

857277-78-1D, 4-[3-Methoxypropyl]-3,5-difluorobenzene

trifluoromethylphenyl]oxy[propoxy]phenyl]piperidin-3-yl]oxy[methyl]-4H-oxazin-3-one 85727-80-6F, text=Butyl (3R,4R)-3-{[4-{3-methoxypropyl}-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy}-4-[4-{3-{[3-trifluoromethylphenyl]oxy}propoxy}phenyl]piperidin

(3*R*, 4*R*)-3-hydroxy-4-[4-[3-[3-(trifluoromethylphenyl)oxy]propoxy]phenyl]piperidine-1-carboxylate
857277-87-9P, 6-[1[(3*R*, 4*R*)-4-[4-[3-(cyclohexyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethyl]-4-(3-

[3R, 4R]-4-[[4-[3-(cyclohexyloxy)propoxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate
850277-85-1E, text=Butyl

to toluene-4-sulfonate 857277-88-4P,
6-[11[3R,4R)-4-[4-(2-{N-methoxy-3-phenoxypropoxy}phenyl)piperidin-3-
yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazolin-3-one
857277-89-5R, Benzyl
{3R,4R)-4-[4-(2-{N-methoxy-3-phenoxypropoxy}phenyl)-

yl)methoxy]piperidine-1-carboxylate 857277-90-8P, Benzyl (3R,4R)-4-[[4-(2-(R)-hydroxy-3-phenoxypropoxy)phenyl]-3-[[4-(2-nethoxypropyl)-2-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)methoxy]piperidine-1-carboxylate 857277-91-9P, Benzyl

benzo[1,4]oxaz[2,6-g]pyrimidin-3-yl)methoxy)piperidine-1-carboxylate 857277-92-0P,
Benzyl (3R,4R)-4-(4-[4-allyloxyphenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-
dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate
857277-93-1P, Benzyl (3R,4R)-4-(4-[4-allyloxyphenyl]-3-hydroxypiperidine-2-
carboxylate 857277-94-2P (3R,4R)-4-(4-[4-allyloxybenzyl]piperidin-3-yl)

857277-94-4P
[3R,4R]-3-[2-[2-hydroxyethyl]phenoxy]ethoxy]-4-[4-[3-[12-methoxybenzyl]oxy]propyl]phenyl]piperidine-1-carboxylate 857278-16-1P,
tert-Butyl [3R,4R]-3-[2-[5-fluoro-2-[2-
[methoxycarbonyl]amino]ethyl]phenoxy]ethoxy]-4-[4-[3-[2-

Methyl N-[2-(4-Fluoro-2-hydroxyphenyl)ethyl]carbamate 857278-22-9P,
Benzyl (3R,4R)-4-[4-[2-(3-Fluorobenzoylamino)ethoxy]phenyl]-3-[[4-(3-
methoxypropyl)-3,4-dihydro-2H-benzo[3,4]oxazin-6-yl]methoxy]piperidine-1-


[illegible][illegible]

ALL ANSWERS HAVE BEEN SCANNED

=> d ibib abs hitrn fhitstr 110 tot

LIO ANMER 2 OF 2
 ACCESSION NUMBER: 2055:58899 CAPLUS
 DOCUMENT NUMBER: 141:12449
 TITLE: Preparation of piperazine as renin inhibitors useful against hypertension and other disorders
 INVENTOR(S): Herold, Peter; Mah, Robert; Stutz, Stefan;
 PATENT(S): Aleksandrov, Tzvetan; Vincenzoni Joturan, Nathalie
 PATENT ASSIGNER(S): Special Experimental A.-G., Zurich, Switzerland
 COUNTRY: PCT Int. Appl., 232 pp.
 DOCUMENT TYPE: OTHER: PCT/EEC
 LANGUAGE: Patent
 English
 FAMILY ACC. SUM. COUNT: 1
 SOURCE: European Patent Office

110 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

[illegible]

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LEUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:115449; MARPAT 143:115449

110 ANSWER 2 OF 72 CAPTURED COPYRIGHT 2009 ACS on STN (Continued)

KLH 8 at O or S & Z is Cl-alk-1-yl-, Cl-alk-2-yl-, Cl-alk-3-yl-, hydroxy-Cl-alk-1-ylidene-, -O-, -S-, -O-alk-, -S-alk-, -alk-O-, -alk-S-, where alk is Cl-alkenyl-, n = 0-1-n, -alk-0-, addl. details are given previously. Alkyl-Alkyl Ether. The methods of prepn. are not claimed, example preps. and/or characterization data 360 T and II are included. For example, III was prepd. from by copolymerization of tert-Bu 4-[4-(3-benzoyloxypropoxy)phenyl]-1-[3-(13-methoxy)phenyl]propanone (I) with tert-butyl 4-carboxyate, which was prepd. by other transformation between tert-Bu 3-hydroxy-4-[4-(3-benzoyloxybenzoyloxy)propoxy]phenyl|piperidine-1-carboxylate and 1-chloroethyl 3-methoxy-5-[3-methoxypropoxy]benzene using

27	BAR 15 DMF		
2044670-79-2	2044670-83-8	2044670-85-0	2044670-88-3
2044670-79-2	2044670-87-2	2044670-87-2	2044670-89-5
2044670-79-2	2044670-87-4	2044670-87-4	2044670-90-8
2044670-79-2	2044670-87-6	2044670-87-6	2044670-91-0
2044670-79-2	2044670-87-7	2044670-87-7	2044670-92-5
2044670-79-2	2044670-87-8	2044670-87-8	2044670-93-1
2044670-79-2	2044670-87-9	2044670-87-9	2044670-93-3
2044670-79-2	2044670-88-0	2044670-88-0	2044670-93-4
2044670-79-2	2044670-88-1	2044670-88-1	2044670-93-5
2044670-79-2	2044670-88-2	2044670-88-2	2044670-93-6
2044670-79-2	2044670-88-3	2044670-88-3	2044670-93-7
2044670-79-2	2044670-88-4	2044670-88-4	2044670-93-8
2044670-79-2	2044670-88-5	2044670-88-5	2044670-93-9
2044670-79-2	2044670-88-6	2044670-88-6	2044670-94-0
2044670-79-2	2044670-88-7	2044670-88-7	2044670-94-1
2044670-79-2	2044670-88-8	2044670-88-8	2044670-94-2
2044670-79-2	2044670-88-9	2044670-88-9	2044670-94-3
2044670-79-2	2044670-89-0	2044670-89-0	2044670-94-4
2044670-79-2	2044670-89-1	2044670-89-1	2044670-94-5
2044670-79-2	2044670-89-2	2044670-89-2	2044670-94-6
2044670-79-2	2044670-89-3	2044670-89-3	2044670-94-7
2044670-79-2	2044670-89-4	2044670-89-4	2044670-94-8
2044670-79-2	2044670-89-5	2044670-89-5	2044670-94-9
2044670-79-2	2044670-89-6	2044670-89-6	2044670-95-0
2044670-79-2	2044670-89-7	2044670-89-7	2044670-95-1
2044670-79-2	2044670-89-8	2044670-89-8	2044670-95-2
2044670-79-2	2044670-89-9	2044670-89-9	2044670-95-3
2044670-79-2	2044670-90-0	2044670-90-0	2044670-95-4
2044670-79-2	2044670-90-1	2044670-90-1	2044670-95-5
2044670-79-2	2044670-90-2	2044670-90-2	2044670-95-6
2044670-79-2	2044670-90-3	2044670-90-3	2044670-95-7
2044670-79-2	2044670-90-4	2044670-90-4	2044670-95-8
2044670-79-2	2044670-90-5	2044670-90-5	2044670-95-9
2044670-79-2	2044670-90-6	2044670-90-6	2044670-96-0
2044670-79-2	2044670-90-7	2044670-90-7	2044670-96-1
2044670-79-2	2044670-90-8	2044670-90-8	2044670-96-2
2044670-79-2	2044670-90-9	2044670-90-9	2044670-96-3
2044670-79-2	2044670-91-0	2044670-91-0	2044670-96-4
2044670-79-2	2044670-91-1	2044670-91-1	2044670-96-5
2044670-79-2	2044670-91-2	2044670-91-2	2044670-96-6
2044670-79-2	2044670-91-3	2044670-91-3	2044670-96-7
2044670-79-2	2044670-91-4	2044670-91-4	2044670-96-8
2044670-79-2	2044670-91-5	2044670-91-5	2044670-96-9
2044670-79-2	2044670-91-6	2044670-91-6	2044670-97-0
2044670-79-2	2044670-91-7	2044670-91-7	2044670-97-1
2044670-79-2	2044670-91-8	2044670-91-8	2044670-97-2
2044670-79-2	2044670-91-9	2044670-91-9	2044670-97-3
2044670-79-2	2044670-92-0	2044670-92-0	2044670-97-4
2044670-79-2	2044670-92-1	2044670-92-1	2044670-97-5
2044670-79-2	2044670-92-2	2044670-92-2	2044670-97-6
2044670-79-2	2044670-92-3	2044670-92-3	2044670-97-7
2044670-79-2	2044670-92-4	2044670-92-4	2044670-97-8
2044670-79-2	2044670-92-5	2044670-92-5	2044670-97-9
2044670-79-2	2044670-92-6	2044670-92-6	2044670-98-0
2044670-79-2	2044670-92-7	2044670-92-7	204467

110 ANSWER 2 OF 2 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)

104673-45-1	104673-46-2	104673-47-3
104673-46-1	104673-47-2	104673-48-3
104673-47-1	104673-48-2	104673-49-3
104673-48-1	104673-49-2	104673-50-3
104673-49-1	104673-50-2	104673-51-3
104673-50-1	104673-51-2	104673-52-3
104673-51-1	104673-52-2	104673-53-3
104673-52-1	104673-53-2	104673-54-3
104673-53-1	104673-54-2	104673-55-3
104673-54-1	104673-55-2	104673-56-3
104673-55-1	104673-56-2	104673-57-3
104673-56-1	104673-57-2	104673-58-3
104673-57-1	104673-58-2	104673-59-3
104673-58-1	104673-59-2	104673-60-3
104673-59-1	104673-60-2	104673-61-3
104673-60-1	104673-61-2	104673-62-3
104673-61-1	104673-62-2	104673-63-3
104673-62-1	104673-63-2	104673-64-3
104673-63-1	104673-64-2	104673-65-3
104673-64-1	104673-65-2	104673-66-3
104673-65-1	104673-66-2	104673-67-3
104673-66-1	104673-67-2	104673-68-3
104673-67-1	104673-68-2	104673-69-3
104673-68-1	104673-69-2	104673-70-3
104673-69-1	104673-70-2	104673-71-3
104673-70-1	104673-71-2	104673-72-3
104673-71-1	104673-72-2	104673-73-3
104673-72-1	104673-73-2	104673-74-3
104673-73-1	104673-74-2	104673-75-3
104673-74-1	104673-75-2	104673-76-3
104673-75-1	104673-76-2	104673-77-3
104673-76-1	104673-77-2	104673-78-3
104673-77-1	104673-78-2	104673-79-3
104673-78-1	104673-79-2	104673-80-3
104673-79-1	104673-80-2	104673-81-3
104673-80-1	104673-81-2	104673-82-3
104673-81-1	104673-82-2	104673-83-3
104673-82-1	104673-83-2	104673-84-3
104673-83-1	104673-84-2	104673-85-3
104673-84-1	104673-85-2	104673-86-3
104673-85-1	104673-86-2	104673-87-3
104673-86-1	104673-87-2	104673-88-3
104673-87-1	104673-88-2	104673-89-3
104673-88-1	104673-89-2	104673-90-3
104673-89-1	104673-90-2	104673-91-3
104673-90-1	104673-91-2	104673-92-3
104673-91-1	104673-92-2	104673-93-3
104673-92-1	104673-93-2	104673-94-3
104673-93-1	104673-94-2	104673-95-3
104673-94-1	104673-95-2	104673-96-3
104673-95-1	104673-96-2	104673-97-3
104673-96-1	104673-97-2	104673-98-3
104673-97-1	104673-98-2	104673-99-3
104673-98-1	104673-99-2	104673-100-3
104673-99-1	104673-100-2	104673-101-3
104673-100-1	104673-101-2	104673-102-3
104673-101-1	104673-102-2	104673-103-3
104673-102-1	104673-103-2	104673-104-3
104673-103-1	104673-104-2	104673-105-3
104673-104-1	104673-105-2	104673-106-3
104673-105-1	104673-106-2	104673-107-3
104673-106-1	104673-107-2	104673-108-3
104673-107-1	104673-108-2	104673-109-3
104673-108-1	104673-109-2	104673-110-3
104673-109-1	104673-110-2	104673-111-3
104673-110-1	104673-111-2	104673-112-3
104673-111-1	104673-112-2	104673-113-3
104673-112-1	104673-113-2	104673-114-3
104673-113-1	104673-114-2	104673-115-3
104673-114-1	104673-115-2	104673-116-3
104673-115-1	104673-116-2	104673-117-3
104673-116-1	104673-117-2	104673-118-3
104673-117-1	104673-118-2	104673-119-3
104673-118-1	104673-119-2	104673-120-3
104673-119-1	104673-120-2	104673-121-3
104673-120-1	104673-121-2	104673-122-

